The company will provide one crore tablets every week, starting from 12th May 2021, aggregating to 16 crore tablets worth Rs. 8 crores over the next 4 months
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The agreement will help ensure wider reach and access to patients in India
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
The additional allocation of Tocilizumab will ensure sufficient availability for COVID-19 patients and augment the government’s efforts to fight the pandemic
Favipiravir is close to Remdesivir, Remdesivir is used to treat moderate to severe cases while Favipiravir is used to treat mild to moderate cases
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
